Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Fontan L, Goldstein R, Casalena G, Durant M, Teater MR, Wilson J, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137(6):788-800.

Sussman RT, Manning B, Ackerman D, Bigdeli A, Pammer P, Velu PD, et al. Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. Cancer Genet. 2021;256-257:68-76.

DeSimone RA, Vinchi F. Screening out the Exposome to Improve Transfusion Quality. Hemasphere. 2021;5(7):e605.

Ma L, Zhao Z, Racine-Brzostek SE, Yang HS. A rare case of persistent pseudohypobicarbonatemia arising from chemistry analyzer-specific interference. Clin Chim Acta. 2021;519:308-310.

Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. bioRxiv. 2021.

Kasashima H, Duran A, Cid-Diaz T, Muta Y, Kinoshita H, Batlle E, et al. Mouse model of colorectal cancer: orthotopic co-implantation of tumor and stroma cells in cecum and rectum. STAR Protoc. 2021;2(1):100297.

Chapel DB, Lee EK, Da Silva AF, Teschan N, Feltmate C, Matulonis UA, et al. Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021;34(3):613-626.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.

Ghantous Y, Omar M, Broner EC, Agrawal N, Pearson AT, Rosenberg AJ, et al. A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2021.

Johnson SM, Khararjian A, Legesse TB, Khani F, Robinson BD, Epstein JI, et al. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6. Am J Clin Pathol. 2021;155(4):588-596.